MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
lenalidomide Sensitive: B - Late Trials
|
lenalidomide Sensitive: B - Late Trials
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
EPOCH-R Sensitive: C3 – Early Trials
|
EPOCH-R Sensitive: C3 – Early Trials
|
MYC rearrangement
|
Mediastinal B Cell Lymphoma
|
MYC rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|
MYC rearrangement
|
Follicular Lymphoma
|
MYC rearrangement
|
Follicular Lymphoma
|
EPOCH-R Sensitive: C3 – Early Trials
|
EPOCH-R Sensitive: C3 – Early Trials
|
MYC rearrangement
|
NHL
|
MYC rearrangement
|
NHL
|
CARMEN Sensitive: C3 – Early Trials
|
CARMEN Sensitive: C3 – Early Trials
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
|
INCB57643 Sensitive: D – Preclinical
|
INCB57643 Sensitive: D – Preclinical
|